Poxel announced on Wednesday that it has postponed the publication of its annual results for 2022 until the end of March, following the conclusion of an agreement on the restructuring of its debt.

In a press release, the biopharmaceutical company specializing in the treatment of NASH and rare metabolic diseases states that it has reached an agreement with its creditors on the restructuring of its debt.

The company - which still has to finalize the documentation relating to this operation - plans to subsequently close its annual accounts for 2022 and complete the associated audit procedures.

The new publication date for the 2022 annual results, scheduled for the end of March, will be communicated in the next few days.

Copyright (c) 2023 CercleFinance.com. All rights reserved.